Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study - Université de Rennes Access content directly
Journal Articles RMD Open Year : 2023

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study

1 CHU Saint-Antoine [AP-HP]
2 ECSTRRA [CRESS - U1153 / UMR_A 1125] - Epidemiology and Clinical Statistics for Tumor, Respiratory, and Resuscitation | Epidémiologie Clinique, STatistique, pour la Recherche en Santé
3 IRCCS San Raffaele Scientific Institute [Milan, Italie]
4 Sechenov First Moscow State Medical University
5 UNIMORE - Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia
6 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
7 UNITO - Università degli studi di Torino = University of Turin
8 OSGB - Ospedale San Giovanni Bosco [Turin, Italy]
9 HJD - Hôpital Joseph Ducuing - Varsovie [Toulouse]
10 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
11 RID-AGE - Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167
12 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
13 TIMONE - Hôpital de la Timone [CHU - APHM]
14 Bnei Zion Hospital [Haifa]
15 Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France / National Reference Center for Rare Systemic Autoimmune Diseases
16 UPCité - Université Paris Cité
17 CHU Caen
18 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
19 Medical Center K-31 [Moscou]
20 Centre Hospitalier Universitaire [Rennes]
21 Irset - Institut de recherche en santé, environnement et travail
22 CHU Rouen
23 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
24 CRI (UMR_S_1149 / ERL_8252 / U1149) - Centre de recherche sur l'Inflammation
25 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
26 CHB - Centre Hospitalier de Blois
27 Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]
28 Université Paris-Saclay
29 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
30 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
31 Centre régional de compétence des Maladies systémiques et auto-immunes rares de l'adulte et Maladies vasculaires rares
32 CHU Rothschild [AP-HP]
33 UNEOS
34 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
35 UB - Université de Bourgogne
36 HCL - Hospices Civils de Lyon
37 Université de Lyon
38 Hedi Chaker Hospital [Sfax]
39 CH Rochefort - Centre Hospitalier de Rochefort
40 UT - Université de Tours
41 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
42 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
43 CHU La Réunion - Centre Hospitalier Universitaire de La Réunion
44 Nippon Medical School [Tokyo, Japon]
45 IRCCS Messina - Centro Neurolesi Bonino Pulejo Messina
46 Nairi hospital [Erevan]
47 Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
48 CHU Pitié-Salpêtrière [AP-HP]
Achille Aouba
  • Function : Author
Ygal Benhamou
  • Function : Author
Thomas Sené
Francois Maurier
  • Function : Author
Alexandre Belot
Masataka Kuwana
Alberto Lo Gullo
Olivier Fain

Abstract

Objectives: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.Methods: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.Results: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. Among them, 91 and 18 patients received intravenous and SC tocilizumab, respectively. A complete response (NIH <2 with less than 7.5 mg/day of prednisone) at 6 months was evidenced in 69% of TAK patients, of whom 57 (70%) and 11 (69%) patients were on intravenous and SC tocilizumab, respectively (p=0.95). The factors associated with complete response to tocilizumab at 6 months in multivariate analysis, only age <30 years (OR 2.85, 95% CI 1.14 to 7.12; p=0.027) and time between TAK diagnosis and tocilizumab initiation (OR 1.18, 95% CI 1.02 to 1.36; p=0.034). During the median follow-up of 30.1 months (0.4; 105.8) and 10.8 (0.1; 46.4) (p<0.0001) in patients who received tocilizumab in intravenous and SC forms, respectively, the risk of relapse was significantly higher in TAK patients on SC tocilizumab (HR=2.55, 95% CI 1.08 to 6.02; p=0.033). The overall cumulative incidence of relapse at 12 months in TAK patients was at 13.7% (95% CI 7.6% to 21.5%), with 10.3% (95% CI 4.8% to 18.4%) for those on intravenous tocilizumab vs 30.9% (95% CI 10.5% to 54.2%) for patients receiving SC tocilizumab. Adverse events occurred in 14 (15%) patients on intravenous route and in 2 (11%) on SC tocilizumab.Conclusion: In this study, we confirm that tocilizumab is effective in TAK, with complete remission being achieving by 70% of disease-modifying antirheumatic drugs-refractory TAK patients at 6 months.

Dates and versions

hal-04164662 , version 1 (18-07-2023)

Licence

Attribution - NonCommercial

Identifiers

Cite

Arsène Mekinian, Lucie Biard, Dagna Lorenzo, Pavel Novikov, Carlo Salvarani, et al.. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open, 2023, 9 (2), pp.e002830. ⟨10.1136/rmdopen-2022-002830⟩. ⟨hal-04164662⟩
46 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More